Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmuCellFRA:IUL +1.22%55 Receivables Turnover is 2.57 as of Jun. 2026. GuruFocus rates FRA:IUL with a GF Score™ of 55/100 and a GF Value™ of €5.66 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 847 Biotechnology companies, ImmuCell ranks better than 81.23% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. ImmuCell's Revenue for the
three
months ended in Jun. 2026 was €6.24 Mil. ImmuCell's average Accounts Receivable for the
three
months ended in Jun. 2026 was €2.42 Mil.
Hence, ImmuCell's Receivables Turnover for the
three
months ended in Jun. 2026 was 2.57.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
ImmuCell Receivables Turnover Related Terms
ImmuCell Receivables Turnover Historical Data
* Premium members only.
The historical data trend for ImmuCell's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IUL vs COYA, ENTX, BDTX: Receivables Turnover Comparison
For the Biotechnology subindustry, ImmuCell's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuCell Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ImmuCell's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where ImmuCell's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmuCell (FRA:IUL) has a Receivables Turnover of 2.57 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on ImmuCell and its competitors. According to the industry distribution chart, ImmuCell ranks #159 out of 847 companies in the Biotechnology industry, placing it in the top 18.8%.
Is ImmuCell's Receivables Turnover too high?
ImmuCell's current Receivables Turnover is 2.57. The Biotechnology industry median Receivables Turnover is 5.27. ImmuCell's value of 2.57 is 51.2% below this industry median. Based on the distribution chart, ImmuCell ranks #159 out of 847 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ImmuCell has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's Receivables Turnover compare to COYA and ENTX?
According to the Biotechnology industry distribution chart, ImmuCell ranks #159 out of 847 companies for Receivables Turnover. This places ImmuCell in the top 19% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.27. ImmuCell's value of 2.57 is 51.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ImmuCell's current Receivables Turnover of 2.57 is 51.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on ImmuCell and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ImmuCell's current Receivables Turnover is 2.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (FRA:IUL) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.66, compared to a current price of €8.30 — trading 46.6% above its estimated fair value. The current Receivables Turnover is 2.57 and 51.2% below the Biotechnology industry median of 5.27. ImmuCell's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For ImmuCell (FRA:IUL), the current Receivables Turnover is 2.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ImmuCell (FRA:IUL) Overvalued in 2026?
Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued.
The current stock price of €8.30 is trading 46.6% above its estimated GF Value™ of €5.66.
GuruFocus considers ImmuCell to be Significantly Overvalued.
Key valuation signals for FRA:IUL:
Receivables Turnover: 2.57
GF Value™: €5.66 vs. price of €8.30 (46.6% above fair value)
Industry Position: 51.2% below the Biotechnology median (#159 of 847)
No single metric tells the full story. See the FRA:IUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
55GF Score
Get the complete analysis for FRA:IUL
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IUL has been successfully added to your 
